Crandell Keith's Form 4 filing
Neumora Therapeutics, Inc. (NMRA) · filed Sep 27, 2023
- Accession no.
- 0001062993-23-018547
- Filed
- Sep 27, 2023, 8:18 PM ET
- Trade date
- Sep 26-27, 2023
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions. Open-market purchases total $700.5K. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Crandell KeithCIK 0001219039 | 10% Owner |
| Nelsen RobertCIK 0001219042 | 10% Owner |
| Gillis StevenCIK 0001229592 | 10% Owner |
| ARCH Venture Fund XII, L.P.CIK 0001906837 | 10% Owner |
| ARCH Venture Partners XII, LLCCIK 0001979548 | 10% Owner |
| ARCH Venture Partners XII, L.P.CIK 0001979765 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 26, 2023 | Common Stock | PPurchaseAcquired | +34,000 | $11.73 | +$398,820 | 3,758,883 | Indirect | Duplicate filing |
| Sep 27, 2023 | Common Stock | PPurchaseAcquired | +24,504 | $12.31 | +$301,644.24 | 3,783,387 | Indirect | Duplicate filing |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.